000909091 001__ 909091
000909091 005__ 20230123110639.0
000909091 0247_ $$2doi$$a10.3389/fmolb.2021.816166
000909091 0247_ $$2Handle$$a2128/31671
000909091 0247_ $$2pmid$$a35187076
000909091 0247_ $$2WOS$$aWOS:000759912700001
000909091 037__ $$aFZJ-2022-03004
000909091 082__ $$a570
000909091 1001_ $$0P:(DE-HGF)0$$aHernández González, Jorge E.$$b0
000909091 245__ $$aA Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease
000909091 260__ $$aLausanne$$bFrontiers$$c2022
000909091 3367_ $$2DRIVER$$aarticle
000909091 3367_ $$2DataCite$$aOutput Types/Journal article
000909091 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1661170044_2170
000909091 3367_ $$2BibTeX$$aARTICLE
000909091 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000909091 3367_ $$00$$2EndNote$$aJournal Article
000909091 520__ $$aThe SARS-CoV-2 main protease, also known as 3-chymotrypsin-like protease (3CLpro), is a cysteine protease responsible for the cleavage of viral polyproteins pp1a and pp1ab, at least, at eleven conserved sites, which leads to the formation of mature nonstructural proteins essential for the replication of the virus. Due to its essential role, numerous studies have been conducted so far, which have confirmed 3CLpro as an attractive drug target to combat Covid-19 and have reported a vast number of inhibitors and their co-crystal structures. Despite all the ongoing efforts, D-peptides, which possess key advantages over L-peptides as therapeutic agents, have not been explored as potential drug candidates against 3CLpro. The current work fills this gap by reporting an in silico approach for the discovery of D-peptides capable of inhibiting 3CLpro that involves structure-based virtual screening (SBVS) of an in-house library of D-tripeptides and D-tetrapeptides into the protease active site and subsequent rescoring steps, including Molecular Mechanics Generalized-Born Surface Area (MM-GBSA) free energy calculations and molecular dynamics (MD) simulations. In vitro enzymatic assays conducted for the four top-scoring D-tetrapeptides at 20 μM showed that all of them caused 55-85% inhibition of 3CLpro activity, thus highlighting the suitability of the devised approach. Overall, our results present a promising computational strategy to identify D-peptides capable of inhibiting 3CLpro, with broader application in problems involving protein inhibition.
000909091 536__ $$0G:(DE-HGF)POF4-5241$$a5241 - Molecular Information Processing in Cellular Systems (POF4-524)$$cPOF4-524$$fPOF IV$$x0
000909091 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000909091 7001_ $$0P:(DE-Juel1)179561$$aEberle, Raphael J.$$b1$$ufzj
000909091 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b2$$ufzj
000909091 7001_ $$0P:(DE-Juel1)180738$$aCoronado, Mônika A.$$b3$$eCorresponding author$$ufzj
000909091 770__ $$aInteraction of Biomolecules and Bioactive Compounds with the SARS-CoV-2 Proteins: Molecular Simulations for the fight against Covid-19
000909091 773__ $$0PERI:(DE-600)2814330-9$$a10.3389/fmolb.2021.816166$$gVol. 8, p. 816166$$p816166$$tFrontiers in molecular biosciences$$v8$$x2296-889X$$y2022
000909091 8564_ $$uhttps://juser.fz-juelich.de/record/909091/files/fmolb-08-816166.pdf$$yOpenAccess
000909091 8767_ $$d2022-12-19$$eAPC$$jDeposit$$lDeposit: Frontiers$$z2507,50 USD
000909091 909CO $$ooai:juser.fz-juelich.de:909091$$pdnbdelivery$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire
000909091 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)179561$$aForschungszentrum Jülich$$b1$$kFZJ
000909091 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b2$$kFZJ
000909091 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180738$$aForschungszentrum Jülich$$b3$$kFZJ
000909091 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5241$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x0
000909091 9141_ $$y2022
000909091 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000909091 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000909091 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000909091 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-18
000909091 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-18
000909091 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000909091 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-18
000909091 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-08-18
000909091 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000909091 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-08-18
000909091 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-22
000909091 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-22
000909091 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T12:25:52Z
000909091 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T12:25:52Z
000909091 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-11T12:25:52Z
000909091 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-22
000909091 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-22
000909091 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-22
000909091 920__ $$lno
000909091 9201_ $$0I:(DE-Juel1)IBI-7-20200312$$kIBI-7$$lStrukturbiochemie$$x0
000909091 9801_ $$aFullTexts
000909091 980__ $$ajournal
000909091 980__ $$aVDB
000909091 980__ $$aUNRESTRICTED
000909091 980__ $$aI:(DE-Juel1)IBI-7-20200312
000909091 980__ $$aAPC